Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04095936 | Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia | PHASE2 | COMPLETED | 24 | — | — | Dec 3, 2019 | Oct 29, 2021 | May 26, 2022 | 1 | Japan |
| Arm | Type | Description |
|---|---|---|
| AMG531 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Romiplostim | DRUG | Subcutaneous administration of 0 to 20ug/kg for 6 months |
Inclusion Criteria: 1. Voluntary signed informed consent to participate in the study; 2. A diagnosis of AA confirmed by blood and bone-marrow examinations, etc.; 3. Considered to require new treatment with immunosuppressive therapy provided that NSAA must be platelet or erythrocyte transfusion-depe...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 1 | — | Anti-human thymocyte immunoglobulin, equine |
| Novartis AG Sponsored ADR | NVS | 1 | — | Undisclosed |